SCHEMBL4593218

SCHEMBL4593218

Cc1cc(N)ccc1-c1nc2ccccc2s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.65
KDM4E B2RXH2 6/20 0.65
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
NPC1 O15118 4/20 0.65
RAB9A P51151 4/20 0.65
GAA P10253 4/20 0.65
APP P05067 4/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
TDP1 Q9NUW8 2/20 0.65
L3MBTL1 Q9Y468 2/20 0.65
POLB P06746 1/20 0.65
THRB P10828 1/20 0.65
ALOX15 P16050 1/20 0.65
CASP1 P29466 1/20 0.65
SNCA P37840 1/20 0.65
CASP7 P55210 1/20 0.65
HSD17B10 Q99714 1/20 0.65
ALDH1A1 P00352 4/20 0.62
MMP9 P14780 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13281364 0.86 KDM4E (0.75) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL10414016 0.84 KDM4E (0.64) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL12422169 0.84 MAPT (0.67) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL4592720 0.83 MAPT (0.81) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL1977551 0.82 MAPT (0.65) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL31120341 0.82 MAPT (0.57) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL4593570 0.82 KDM4E (0.65) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL9018539 0.82 MAPT (0.54) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL29478088 0.81 KDM4E (0.73) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL20380097 0.81 KDM4E (0.73) MAPTKDM4EMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895313-B2 Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-11-25 US disclosed
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. 2011-07-14 US disclosed
EP-1910349-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2008-04-16 EP disclosed
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES MAPT, PRNP, MAP4 MAPT 1/4885KDM4E 4073/4885MEN1 3205/4885
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 MAPT 4822/4885KDM4E 2243/4885MEN1 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.